Advertisement

Rosiglitazone Effect on Radioiodine Uptake in a Case of Dedifferentiated Thyroid Carcinoma

  • Gülin Uçmak
  • Burcu Esen Akkaş
Chapter

Abstract

Differentiated thyroid cancer may lose its differential characteristics and transform to a less-differentiated form that does not concentrate radioiodine. These tumors represent an aggressive tumor type and may necessitate alternative therapies. Various attempts have been made to augment iodine uptake and to redifferentiate tumors in order to regain benefit from radioiodine therapy. Thiazolidinediones, such as rosiglitazone, act by binding to peroxisome proliferator-activated receptors (PPARs) and have also shown promise in the redifferentiation treatment of dedifferentiated thyroid carcinomas as antiproliferative and apoptosis-inducing agents. In this section, the effect of rosiglitazone is discussed in a case with dedifferentiated thyroid cancer.

References

  1. 1.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefGoogle Scholar
  2. 2.
    Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:313–9.CrossRefGoogle Scholar
  3. 3.
    Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458–60.CrossRefGoogle Scholar
  4. 4.
    Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli J, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960–7.CrossRefGoogle Scholar
  5. 5.
    Capdevila J, Argiles G, Rodriguez-Frexinos V, Nunez I, Tabernero J. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era. Discov Med. 2010;9:153–62.PubMedGoogle Scholar
  6. 6.
    Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.CrossRefGoogle Scholar
  7. 7.
    Spitzweg C, Bible KC, Hofbauer LC, Morris JC. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014;2:830–42.  https://doi.org/10.1016/S2213-8587(14)70051-8.CrossRefPubMedGoogle Scholar
  8. 8.
    Oh SW, Paeng JC, Chung J. New strategies for combined radioiodine therapy in refractory thyroid cancer. J Korean Thyroid Assoc. 2015;8:26–35.CrossRefGoogle Scholar
  9. 9.
    Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane. Endocr Relat Cancer. 2006;13:257–69.CrossRefGoogle Scholar
  10. 10.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.  https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rosario PW, Mourão GF, dos Santos JB, Calsolari MR. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? Thyroid. 2014;24:533–6.  https://doi.org/10.1089/thy.2013.0427.CrossRefPubMedGoogle Scholar
  12. 12.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37:953–9.  https://doi.org/10.1097/RLU.0b013e31825b2057.CrossRefPubMedGoogle Scholar
  13. 13.
    Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging. 2010;44:4–14.  https://doi.org/10.1007/s13139-009-0016-1.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015;21:1028–35.  https://doi.org/10.1158/1078-0432.CCR-14-2915.CrossRefPubMedGoogle Scholar
  15. 15.
    Schreck R, Schnieders F, Schmutzler C, Köhrle J. Retinoids stimulate type I 50-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1994;79:791–8.PubMedGoogle Scholar
  16. 16.
    Oh SW, Moon SH, Park DJ, Cho BY, Jung KC, Lee DS, et al. Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38:1798–805.  https://doi.org/10.1007/s00259-011-1849-2.CrossRefPubMedGoogle Scholar
  17. 17.
    Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86:2170–7.PubMedGoogle Scholar
  18. 18.
    Day C. Thiazolidinediones a new class of antidiabetic drugs. Diabet Med. 1999;16:179–92.CrossRefGoogle Scholar
  19. 19.
    Philips JC, Petite C, Willi JP, Buchegger F, Meier CA. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun. 2004;25:1183–6.CrossRefGoogle Scholar
  20. 20.
    Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer. 2005;12:291–303.CrossRefGoogle Scholar
  21. 21.
    Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid. 2005;15:222–31.  https://doi.org/10.1089/thy.2005.15.222.CrossRefPubMedGoogle Scholar
  22. 22.
    Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R, Greenspan FS. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid. 2009;19:953–6.  https://doi.org/10.1089/thy.2008.0371.CrossRefPubMedGoogle Scholar
  23. 23.
    Rosenbaum-Krumme SJ, Freudenberg LS, Jentzen W, Bockisch A, Nagarajah J. Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by 124I PET/CT imaging. Clin Nucl Med. 2012;37:e47–52.  https://doi.org/10.1097/RLU.0b013e3182443ca6.CrossRefPubMedGoogle Scholar
  24. 24.
    Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid. 2008;18:697–704.  https://doi.org/10.1089/thy.2008.0056.CrossRefPubMedGoogle Scholar
  25. 25.
    Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:213–20.CrossRefGoogle Scholar
  26. 26.
    Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318–26.CrossRefGoogle Scholar
  27. 27.
    Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411–8.  https://doi.org/10.1001/jama.2010.920.CrossRefPubMedGoogle Scholar
  28. 28.
    Rosenbaum-Krumme SJ, Bockisch A, Nagarajah J. Pioglitazone therapy in progressive differentiated thyroid carcinoma. Nuklearmedizin. 2012;51:111–5.  https://doi.org/10.3413/Nukmed-0474-12-01.CrossRefPubMedGoogle Scholar
  29. 29.
    Dobson ME, Diallo-Krou E, Grachtchouk V, Yu J, Colby LA, Wilkinson JE, et al. Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. Endocrinology. 2011;152(11):4455–65.  https://doi.org/10.1210/en.2011-1178.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Raman P, Koenig RJ. Pax-8-PPAR-gamma fusion protein in thyroid carcinoma. Nat Rev Endocrinol. 2014;10:616–23.  https://doi.org/10.1038/nrendo.2014.115.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Gülin Uçmak
    • 1
  • Burcu Esen Akkaş
    • 1
  1. 1.Department of Nuclear MedicineUniversity of Health Sciences (SBÜ) Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalAnkaraTurkey

Personalised recommendations